Molecule News and Research

RSS

FairJourney Bio and AbTherx partner to offer fully integrated antibody discovery

FairJourney Bio (“FJBio”), a global antibody discovery expert, has entered a partnership with AbTherx, Inc. to bring transgenic mouse-based antibody discovery in-house. The agreement gives the Company access to AbTherx’s Atlas™ Full Human Diversity (FHD) and Common Light Chain (cLC) mouse technologies, completing a discovery route that partners can now run end to end entirely within FJBio’s integrated workflow.

From FairJourney Biologics S.A. 24 Jun 2026

Study uncovers sex-specific immune pathway driving glioblastoma growth

Researchers have identified a critical biological difference in how glioblastoma develops in male and female laboratory models, pinpointing an immune pathway that fuels tumor growth only in females.

23 Jun 2026

Scientists uncover new molecular mechanism driving gastrointestinal stromal tumors

Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the digestive tract, with KIT mutations driving approximately 75% to 80% of cases.

23 Jun 2026

TRIMTECH Therapeutics brings total seed round to $47 M with additional investment of $14 M to further develop TRIMTAC and TRIMGLUE targeted protein degradation portfolio

TRIMTECH Therapeutics, a biotechnology company developing novel small molecule therapies that target and degrade protein aggregates associated with neurodegenerative diseases, today announced it has raised an additional $14 million in seed funding, bringing the total for the round to $47 million (£35 million).

From TRIMTECH Therapeutics 23 Jun 2026

Insilico and SK Biopharmaceuticals partner to develop AI-driven neuroimmune therapies

Insilico Medicine, a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, and SK Biopharmaceuticals, a Korean-based company leads the way in biotech innovation with groundbreaking drug research, development, and commercialization worldwide, announced a research and development collaboration at the BIO 2026 International Convention to discover AI-enabled innovative drug candidates in the neuroimmune area of the central nervous system.

22 Jun 2026

Prime and pull vaccine approach prevents genital herpes infection

Genital herpes is a lifelong infection. While available treatments can manage symptoms, they cannot cure the infection or prevent transmission.

22 Jun 2026

UCLA researcher receives grant for advanced osteosarcoma immunotherapy

Physician-scientist Theodore Scott Nowicki, MD, PhD, an assistant professor in the department of pediatrics hematology/oncology and microbiology, immunology, & molecular genetics at the David Geffen School of Medicine at UCLA, has been awarded the Hero Grant from MIB Agents, a nonprofit organization dedicated to improving outcomes for children and young adults with osteosarcoma.

22 Jun 2026

Natural molecule erucamide helps slow progressive retinal degeneration

Many conditions that cause vision loss share a common feature: the gradual breakdown of the retina, the light-sensing tissue at the back of the eye.

22 Jun 2026

Pheno Therapeutics granted FDA IND clearance for lead multiple sclerosis therapeutic candidate PTD802

Pheno Therapeutics Limited. (Pheno), a clinical stage biotechnology company focused on the discovery and development of small molecule therapeutics for the treatment of neurological diseases, today announced that the US Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for PTD802, the Company's lead therapeutic candidate.

From Pheno Therapeutics 22 Jun 2026

Accelerating drug discovery through AI, automation, and next-generation DMTA

Discover how AI, automation, and next-generation DMTA workflows are accelerating drug discovery with expert insights from TTP leaders.

From TTP plc 19 Jun 2026

Breast milk nutrient boosts long-term immune system development

Trans-vaccenic acid (TVA), the most abundant trans fatty acid found in human breast milk, helps boost immune system development and has long-lasting effects on immune system health in mice, according to a new study by researchers from the University of Chicago.

18 Jun 2026

Brazilian researchers identify cell molecule that drives cancer progression

Researchers at the Federal University of São Paulo (UNIFESP) in Brazil have identified a molecule on the surface of cells that could be a promising therapeutic target against cancer.

18 Jun 2026

Epigenetic drugs improve blood vessel health in obesity and diabetes

People with obesity and type 2 diabetes are at high risk of blood vessel damage. This risk depends not only on the genes a person carries, but also on how they are "read".

18 Jun 2026

Deep learning identifies novel compounds against antibiotic-resistant gonorrhea

With tens of millions of annual cases, gonorrhea is the second most frequently reported sexually transmitted infection (STI). Alone in the U.S., over 600,000 cases are reported each year.

17 Jun 2026

Key Alzheimer's protein actively protects neurons from nuclear damage

Researchers at Niigata University's Brain Research Institute have uncovered a new function of amyloid precursor protein (APP), a molecule long studied as the precursor to amyloid-β (Aβ) in Alzheimer's disease (AD).

17 Jun 2026

AI-designed drug for Parkinson's begins first human trial

Insilico Medicine ("Insilico", HKEX: 3696), a clinical-stage biotechnology company powered by generative artificial intelligence (AI), today announced it has achieved the first clinical milestone in its co-development collaboration with Hygtia Therapeutics with the completion of first-in-human dosing in the Phase I study of ISM8969.

17 Jun 2026

Scientists identify unique receptor that accelerates early neuron growth

Cells have surface receptors that couple to proteins and other molecules to initiate or inhibit certain behaviors.

17 Jun 2026

Targeting immune cells could improve colorectal cancer treatments

Researchers at the Medical University of Vienna have described a mechanism in metastatic colorectal cancer that has received little attention to date: a key target of existing therapies, the so-called epidermal growth factor receptor (EGFR), is likely to affect more than just the cancer cells themselves.

17 Jun 2026

Age-related muscle loss linked to increased tumor growth

Duke-NUS scientists have discovered that aging muscle may contribute to cancer growth by releasing fewer extracellular vesicles, tiny particles that cells use to communicate with one another.

16 Jun 2026

New study uncovers how prostate cancer cells evade treatment

Cancer cells are remarkably good at adapting to stress. When treatments damage them, they often find new ways to survive, fueling drug resistance and disease progression.

16 Jun 2026